REVIEW OF DECISIONS

BOARD MEETING
1-2 July 2026, Virtual meeting

Decision 1: Consent Agenda: IRC Chair and Investment Committee Chair appointments

The Gavi Alliance Board:

- **Appointed Dr. Rana Hajjeh** as Independent Review Committee (IRC) Chair for a 3-year term, effective immediately.
- **Appointed Henry Gonzalez,** as an Unaffiliated Board Member, effective 1 November 2026 and until 31 October 2029.
- **Appointed Henry Gonzalez**, as Chair of the Investment Committee, effective 1 November 2026 and until 31 December 2027.

Decision 2: Consent Agenda: Board Vice Chair Appointment

The Gavi Alliance Board:

- **Appointed Mekdes Daba**, as Vice Chair of the Board with individual signatory authority, effective 1 October 2026 and until 30 September 2028.
- **Appointed Mekdes Daba**, as Chair of the Governance Committee, effective 1 October 2026 and until 31 December 2027.

Decision 3: Consent Agenda: Gavi 6.0 Market Shaping Strategy

The Gavi Alliance Board:

- **Approved** the Market Shaping Strategy 6.0 attached as Annex A to Doc 01d.

Decision 4: Alliance Roles and Responsibilities: Addition to Global/Regional Foundations Budget

The Gavi Alliance Board:

- **Approved** the allocation of an additional US$ 30 million to the Foundational Fund, increasing total Global/Regional Foundations resourcing to US$ 190 million, to address high-priority risks.

Decision 5: Amendment and utilisation of the European Investment Bank (EIB) Frontloading Facility

The Gavi Alliance Board:

a) **Approved** the ratification of the amendment to the European Investment Bank (EIB) Frontloading Facility executed by the Chief Executive Officer in December 2025 as set out in Annex B to Doc 06a; and

b) **Approved** the utilisation of the EIB Frontloading Facility through drawdowns of up to EUR 500 million, subject to satisfaction of all conditions precedent.

Gavi
The Vaccine Alliance

Decision 6: African Vaccine Manufacturing Accelerator (AVMA) (1/2)

The Gavi Alliance Board:

a) **Approved** the programming of the additional US$ 189 million in African Vaccine Manufacturing Accelerator (AVMA) pledges above the Board-approved US$ 1 billion ceiling in support of a time-limited addendum to the AVMA key terms as set out in Annex A to Doc 06b, known as “AVMA+”;

b) **Approved** the creation of two new funding windows within AVMA (i) a Vaccine Buy-Down Window and (ii) an Ecosystem Support Window;

c) **Approved** the size of US$ 50 million (with the following allocation: up to USD 25 million to Africa CDC; up to USD 20 million to WHO; up to USD 5 million to AMA), targeted at the most critical risks to AVMA’s delivery for the Ecosystem Support Window, with remaining funds allocated to the Vaccine Buy-down Window. If at the end of 2030 there are undisbursed funds in the Ecosystem Support Window, these funds will be transferred to the Vaccine Buy-down Window;

d) **Requested** the Secretariat to include information each year in the AVMA annual report on the key indicators and disbursement levels from the Ecosystem window to ensure the activities are effectively implemented, remaining relevant and deliverable within the Gavi 6.0 strategic period. Depending on the reports, the Board may assess the need for any adjustments;

Decision 6: African Vaccine Manufacturing Accelerator (AVMA) (2/2)

e) **Requested** the Secretariat provide to the Programme and Policy Committee in October 2026 and to the Board in December 2026 proposals on an accelerated course-correction to AVMA's key terms limited at this stage to: (i) Accelerator payment levels (including the per-vial fill-finish cap) and (ii) scope of vaccines eligible for Milestone payments to take account of the changed operating context since AVMA's launch in 2024. Updated incentive levels will be considered to all AVMA-eligible doses procured through upcoming UNICEF tenders; and

f) **Approved** an additional amendment to AVMA's key terms to ensure that any eligible African manufactured vaccines which receive WHO Emergency Use Listing for Bundibugyo virus disease (BVD), qualify for AVMA incentives.

Decision 7: Financial Update, including forecast

The Gavi Alliance Board:

a) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations made by the Programme and Policy Committee (PPC) and concluded that the recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy;

b) **Approved** the Gavi 6.0 Financial Forecast (2026-2030) of Qualifying Resources of US$ 9.3 billion (including US$ 0.2 billion of AVMA+ resources which, subject to Board approval, could support Gavi 6.0 programmes) and Forecast Expenditure of US$ 10.2 billion, noting that the Gavi 6.0 Financial Forecast (2026-2030) Resources are US$ 10.2 billion and the Secretariat will only commit funds aligned with available Qualifying Resources and cash flow forecasts; and

c) **Approved** the 2026–2030 forecast for other Board approved, funded programmes of Forecast Resources of US$ 2.0 billion and Forecast Expenditure of US$ 0.5 billion (the African Vaccine Manufacturing Accelerator (AVMA), the Pandemic Prevention Preparedness and Response (PPPR) coalition, the First Response Fund (FRF) and legacy COVAX AMC funded programmes) noting that this includes (i) US$ 50 million drawdown from the FRF to support the Alliance's response to the Ebola Bundibugyo Virus (BVD) outbreak and (ii) up to US$ 0.2 billion which, subject to Board approval, could support Gavi 6.0 through AVMA+ programming.

Gavi
The Vaccine Alliance

Decision 8: Gavi Alliance Risk Appetite Statement

The Gavi Alliance Board:

- **Approved** the Gavi Alliance Risk Appetite Statement version 4.0 attached as Annex A to Doc 08.

Decision 9: Vaccine Budget Policy

The Gavi Alliance Board:

a) **Approved** the Vaccine Budget Policy attached as Annex B to Doc 09.

b) **Noted** that:

   i. Additional resources in the financial forecast v23.2 (approximately US$ 222 million) will be allocated to countries following the revised approach. This would likely cover most of the additional 2026 and 2027 needs from the draft v23.2 financial forecast.

   ii. If a funding gap in guaranteed budgets and the Initial Self Financing (ISF) floor persists, the Secretariat will conduct a holistic review of all Gavi funding envelopes to fill that gap and bring it to the Board for decision.

   iii. The Alliance will conduct a review of the Vaccine Budget policy in 2028 and update it as needed with Gavi Alliance Board approval.

c) **Noted** that additional donor resources available to Gavi (if any) will be allocated to fill the remaining funding gap in guaranteed budgets and the Initial Self-Financing floor pending Audit and Finance Committee confirmation of funding availability.

Decision 10: Health Systems and Immunisation Strengthening Policy

The Gavi Alliance Board:

- **Approved** the Health Systems and Immunisation Strengthening Policy attached as Annex B to Doc 10.

Decision 11: Strategic Approach on Campaign Optimisation

The Gavi Alliance Board:

a) **Approved** the Campaign Optimisation Strategic Approach as outlined in Annex C to Doc 11, as amended by the Board; and

b) **Approved** the updated Co-financing Policy attached as Annex D to Doc 11, as amended by discussions at the Board to set campaign co-financing rates for initial self-financing, preparatory and accelerated transition countries at 2% (as of January 2027), 10% and 20% respectively, and to expand the scope of the campaign co-financing reduction to include integration with non-Gavi funded polio immunisation campaigns.

Decision 12: Fragile and Humanitarian Approach

The Gavi Alliance Board:

- **Approved** the proposed reprioritisation of use cases under the Fragile & Humanitarian Approach attached as Annex A to Doc 12.

Decision 13: Ukraine Fragility Support

The Gavi Alliance Board:

a) **Approved, exceptionally:** (1) a no-cost extension of Ukraine's US$ 10 million fragility support as approved by the Gavi Board in December 2025, from 1 July 2026 until 30 June 2027; and (2) a costed extension of US$ 6 million until 31 December 2027 contingent on additional funds being available through a special programme to support Ukraine.

b) **Requested** that the Secretariat explores alternative funding mechanisms to finance the Gavi Board approved US$ 10 million fragility support to release pressure from the funds in the Gavi Resilience Mechanism.

Decision 14: Gavi 6.0 Measurement Framework Targets

The Gavi Alliance Board:

a) **Approved** the Gavi 6.0 mission and strategy measurement framework targets attached as Annex B to Doc 14; and

b) **Noted** the update on the evidence prioritisation approach and Evaluation Policy revision process.

Thank you